Bridging the divide between discovery and delivering patient-specific medicines is the goal of many biotech companies. Our unique approach utilises Tay Therapeutics’ technology platform coupled to in-house discovery and development expertise to deliver substantial improvements in patient care.
LATEST NEWS
June 13, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
June 5, 2024
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
November 2, 2021
In4Derm announces a £1.6m pre-Series A funding round to support the continued development and expansion of its pipeline of first-in-class anti-inflammatory and orphan indications therapeutics